Thursday, 23 April 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 23 April 2026
Ascott 2
Ascott 2
Aussie pharma naughty or nice?

With more than 10 Code of Conduct complaints in three years resulting in more than $1.3 million in fines, is Australia's pharma industry playing nice when it comes to accusing rivals of code breaches?

One of industry's best moves on
Two-time PRIME Awards winner lands a new job outside industry at 'one of the fastest growing companies since Canva'
TODAY
Gene therapy finds footing in Aust
Who's secured a licence to conduct studies of its FDA-approved intravesical gene therapy in Australia?
TODAY
Final contender in MA Board race
Voting is now open to fill four vacancies on the Medicines Australia Board with an official count of 10 leaders in the running
22 April
From napkin to buyout in 10 years
An Australian pharma consulting firm with almost 500 market access projects under its belt now has international backing
22 April
Meet the most profitable pharma
The top 13 most profitable pharmas named with one company, which had an 83 per cent gross margin, branded the standout
21 April
Best drug name of 2026 goes to...
Pharma industry professionals have decided this year's best drug name in a nail-biting final championship round
21 April
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (6)

Sales & Customer Relations (15)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (3)

Executive Roles (1)

Other (9)

J&J chases record-breaking sales
This company has set its sights on an ambitious goal of $100 billion in revenue this year... but analysts aren't so sure
22 April
Oncolytic immunotherapy cleared
CRO wins the go-ahead to conduct a clinical trial in Australia for Akamis Bio's lead drug candidate in rectal cancer
22 April
Another ex-Govt staffer joins MA
Former Chief of Staff to a Cabinet Minister and one-time newsman joins Medicines Australia, to steer Public Affairs and Govt Relations
22 April
Lung cancer drug wins wider label
Expanded approval for use as a combination therapy under the FDA's Project Orbis but it's already been knocked back by the PBAC
21 April
PBS rules preventing best practice
PBAC-imposed restrictions on PBS-listed drugs are preventing clinicians from prescribing the best treatment for their patients
21 April
Gilead builds a new revenue play
With half its revenue coming from a single product, this company is spending big to diversify its earnings
21 April
Jobs go in company streamlining
This company is the latest to streamline its operations with an undisclosed number of job losses
20 April
Drugs jostle for May PBS listing
After two big months for PBS listings, May is shaping up to be much quieter with only seven drugs in the final stage before listing
20 April
Big win for 'high-potential' biotechs
Biointelect and venture-capital-as-a-service firm join forces to advance companies through the critical clinical development
20 April
GSK notches another RSV first
Company racks up its third win in this highly competitive space with its RSV vaccine the first to be added to the NIP for older Aussies
20 April
Two new drugs, first biosim ticked
New antibody-drug conjugate and a new antidote approved by the TGA alongside the first biosim of a Novartis cancer drug
20 April Approvals Action
Leaders pitch for MA Board role
Nine leaders are hoping to join the Medicines Australia Board with nominees pitching their case to fill four vacancies
17 April
Bosses crack the $40M Club
A handful of pharma company leaders have cracked a new milestone with compensation packages north of AU$40M
17 April
No TGA action after patient deaths
ICYMI: Despite 8 overseas deaths and action from the FDA, the TGA is taking a routine approach plus the other popular stories this week
17 April Your Week in 5 Minutes
PiF Advertise
PiF Advertise
Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.